N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
Left Ventricle Function
Primary: Left Ventricular Ejection Fraction (LVEF), Change From Baseline — 2.00; -3.25 Percent change
Phase 3 N=133 PUFAs and Left Ventricular Function in Heart Failure
Dilated Cardiomyopathy · Heart Failure
Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…
Phase 4 N=777 ISCHEMIA-Chronic Kidney Disease Trial
Cardiovascular Diseases · Coronary Artery Disease · Heart Diseases
Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants
N/A N=197 Model 4396 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants
N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Phase 4 N=697 Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease
Ischemic Heart Disease
Primary: Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement — 140 participants
N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
N/A N=523 Risk Stratification in Patients With Preserved Ejection Fraction
Myocardial Infarction
Primary: Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or…
N/A N=319 Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization
Cardiovascular Diseases · Coronary Disease · Heart Failure
Primary: Survival Free of Cardiac Hospitalization
Phase 4 N=300 Clinical Study of Lipoic Acid on Ischemic Heart Failure
Ischemic Heart Failure
Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants
Phase 3 N=882 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Coronary Artery Bypass Grafting · Mitral Valve Surgery · Low Cardiac Output Syndrome
Primary: Number of Dual Efficacy Endpoint Events — 56; 48 events
N/A N=90 Model 4296 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Number of Participants With Left Ventricular (LV)Lead Related Complications — 1 participants
N/A N=111 Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
Mitral Valve Insufficiency · Atrial Fibrillation · Heart Failure
Primary: Left Ventricular Filling Pressure More Than 15 mmHg Measured by Left Ventricular Catheterization — 25.5 mmHg
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Phase 3 N=40 Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Heart Disease, Ischemic · Atherosclerosis, Coronary
Primary: Magnetic Resonance Image Quality Rating — 3.57; 2.55 units on a likert scale — p=<0.001
N/A N=250 IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)
Post MI Left Ventricular Dysfunction
Primary: The Primary Objective of the Study is to Assess Percent of Participants With Clinically Significant Arrhythmias on ELR Post MI — 48.5 percentage of analyzed population
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
N/A N=30 Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients
Renal Dialysis · Hemodiafiltration · Diastolic Dysfunction
Primary: Left Ventricular Diastolic Function Category — 15; 15; 5; 5 Participants — p=0.06
N/A N=101 Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™
Heart Failure
Primary: Six Minute Hall Walk (6MHW) Distance — -44.9; 69.7 meters — p=0.001
Phase 2 N=10 Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices
Heart Failure
Primary: Biologic Efficacy: Inflammation Marker - C-Reactive Protein — 2.5; 0.6; 0.6 mg/dL
Phase 2 N=23 Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
Phase 3 N=72 Impact of Diabetes on Left Ventricular Remodeling
Diabetes
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) — 73.03; 78.06; 78.52; 79.03 ml/m^2
Phase 2 N=58 Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction
Acute Myocardial Infarction
Primary: Change in Left Ventricular End-Systolic Volume Index — -2.1; -4.6 mL of blood/meter^2 body surface area — p=0.97
Phase 4 N=28 Ranolazine in Ischemic Cardiomyopathy
Cardiomyopathy · Chest Pain · Dyspnea
Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058
Phase 2 N=10 Myocardial Hemodynamic Effects of Levosimendan
Heart Failure
Primary: Change in Left Ventricular End-diastolic Pressure (LVEDP) Using Pressure-volume Catheter. — 5.67 mmHg